OptiNose, Inc. (NASDAQ:OPTN) Shares Purchased by Great Point Partners LLC

Great Point Partners LLC increased its stake in shares of OptiNose, Inc. (NASDAQ:OPTN) by 56.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,727,097 shares of the company’s stock after buying an additional 4,940,779 shares during the period. OptiNose comprises 2.7% of Great Point Partners LLC’s portfolio, making the stock its 17th largest holding. Great Point Partners LLC owned 0.12% of OptiNose worth $14,276,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in OPTN. MVM Partners LLC acquired a new stake in shares of OptiNose during the 4th quarter valued at approximately $18,768,000. Kingdon Capital Management L.L.C. grew its holdings in shares of OptiNose by 5.4% in the 4th quarter. Kingdon Capital Management L.L.C. now owns 3,899,237 shares of the company’s stock worth $5,030,000 after acquiring an additional 200,000 shares during the period. HighMark Wealth Management LLC purchased a new position in OptiNose in the 1st quarter valued at approximately $36,000. Easterly Investment Partners LLC raised its holdings in OptiNose by 34.0% during the first quarter. Easterly Investment Partners LLC now owns 2,038,039 shares of the company’s stock worth $2,976,000 after purchasing an additional 516,730 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in OptiNose by 1.5% during the first quarter. Vanguard Group Inc. now owns 4,242,610 shares of the company’s stock worth $6,194,000 after purchasing an additional 62,906 shares in the last quarter. 85.60% of the stock is currently owned by institutional investors and hedge funds.

OptiNose Stock Performance

OptiNose stock opened at $0.72 on Tuesday. The firm has a market capitalization of $81.39 million, a price-to-earnings ratio of -2.67 and a beta of -0.04. OptiNose, Inc. has a fifty-two week low of $0.72 and a fifty-two week high of $2.10. The stock’s fifty day moving average is $0.97 and its two-hundred day moving average is $1.13.

OptiNose (NASDAQ:OPTN) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. The business had revenue of $20.49 million during the quarter, compared to analyst estimates of $20.81 million. As a group, sell-side analysts forecast that OptiNose, Inc. will post -0.22 EPS for the current fiscal year.

Insider Activity

In related news, CEO Ramy A. Mahmoud sold 111,426 shares of OptiNose stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $1.14, for a total transaction of $127,025.64. Following the completion of the transaction, the chief executive officer now directly owns 1,206,978 shares in the company, valued at approximately $1,375,954.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other OptiNose news, insider Michael F. Marino III sold 49,408 shares of the company’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $1.14, for a total value of $56,325.12. Following the transaction, the insider now directly owns 550,464 shares in the company, valued at approximately $627,528.96. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Ramy A. Mahmoud sold 111,426 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $1.14, for a total transaction of $127,025.64. Following the sale, the chief executive officer now directly owns 1,206,978 shares in the company, valued at $1,375,954.92. The disclosure for this sale can be found here. Insiders have sold 167,679 shares of company stock worth $191,154 over the last ninety days. 2.70% of the stock is currently owned by insiders.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.